Graig Suvannavejh
Stock Analyst at Mizuho
(2.44)
# 2,294
Out of 4,784 analysts
150
Total ratings
46.09%
Success rate
-1.86%
Average return
Main Sectors:
Stocks Rated by Graig Suvannavejh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AXSM Axsome Therapeutics | Maintains: Outperform | $212 → $216 | $118.53 | +82.23% | 21 | Mar 27, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Outperform | $42 → $44 | $33.19 | +32.57% | 17 | Mar 18, 2025 | |
| ITCI Intra-Cellular Therapies | Downgrades: Neutral | $140 → $132 | $131.81 | +0.14% | 10 | Feb 24, 2025 | |
| ADAP Adaptimmune Therapeutics | Maintains: Outperform | $3 → $1.5 | $0.21 | +628.16% | 2 | Nov 27, 2024 | |
| AUTL Autolus Therapeutics | Upgrades: Buy | $7 → $7.6 | $1.66 | +357.83% | 1 | Nov 18, 2024 | |
| IMCR Immunocore Holdings | Downgrades: Neutral | $72 → $38 | $29.58 | +28.47% | 7 | Nov 11, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Neutral | $39 → $38 | $24.27 | +56.57% | 6 | Oct 24, 2024 | |
| CRBP Corbus Pharmaceuticals Holdings | Reiterates: Outperform | $74 | $5.52 | +1,240.58% | 1 | Sep 20, 2024 | |
| ATHA Athira Pharma | Downgrades: Neutral | $5 → $0.5 | $0.31 | +63.93% | 3 | Sep 19, 2024 | |
| HALO Halozyme Therapeutics | Maintains: Neutral | $44 → $49 | $63.84 | -23.25% | 6 | Jul 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $17.05 | +193.26% | 1 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $1.03 | +1,841.75% | 1 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $82 | $77.99 | +5.14% | 6 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $16 | $4.63 | +245.57% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $3 | $3.66 | -18.03% | 5 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $39 → $30 | $5.83 | +414.58% | 4 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $22 | $4.61 | +377.22% | 4 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $8 | $1.64 | +387.80% | 1 | Apr 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3.5 | $3.38 | +3.55% | 1 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $10 | $2.92 | +242.47% | 5 | Nov 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $9 | $1.29 | +597.67% | 4 | Nov 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $64 | $2.12 | +2,918.87% | 8 | Aug 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $1 | $1.98 | -49.49% | 5 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $1.91 | +685.34% | 1 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $35 | $54.80 | -36.13% | 5 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $8 | $2.91 | +174.91% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $71 → $57 | $43.19 | +31.97% | 2 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $5 | $39.86 | -87.46% | 4 | Apr 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $7.26 | +368.32% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $4.21 | +565.08% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $31 | $23.27 | +33.22% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $19 | $0.75 | +2,423.58% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $4.75 | $1.98 | +139.90% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $36 | $15.73 | +128.86% | 2 | Nov 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $25.46 | - | 1 | Oct 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $37 | $0.80 | +4,526.74% | 1 | Oct 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $128 | $122.92 | +4.13% | 1 | Sep 14, 2020 |
Axsome Therapeutics
Mar 27, 2025
Maintains: Outperform
Price Target: $212 → $216
Current: $118.53
Upside: +82.23%
Harmony Biosciences Holdings
Mar 18, 2025
Maintains: Outperform
Price Target: $42 → $44
Current: $33.19
Upside: +32.57%
Intra-Cellular Therapies
Feb 24, 2025
Downgrades: Neutral
Price Target: $140 → $132
Current: $131.81
Upside: +0.14%
Adaptimmune Therapeutics
Nov 27, 2024
Maintains: Outperform
Price Target: $3 → $1.5
Current: $0.21
Upside: +628.16%
Autolus Therapeutics
Nov 18, 2024
Upgrades: Buy
Price Target: $7 → $7.6
Current: $1.66
Upside: +357.83%
Immunocore Holdings
Nov 11, 2024
Downgrades: Neutral
Price Target: $72 → $38
Current: $29.58
Upside: +28.47%
Apellis Pharmaceuticals
Oct 24, 2024
Maintains: Neutral
Price Target: $39 → $38
Current: $24.27
Upside: +56.57%
Corbus Pharmaceuticals Holdings
Sep 20, 2024
Reiterates: Outperform
Price Target: $74
Current: $5.52
Upside: +1,240.58%
Athira Pharma
Sep 19, 2024
Downgrades: Neutral
Price Target: $5 → $0.5
Current: $0.31
Upside: +63.93%
Halozyme Therapeutics
Jul 22, 2024
Maintains: Neutral
Price Target: $44 → $49
Current: $63.84
Upside: -23.25%
Jul 8, 2024
Initiates: Outperform
Price Target: $50
Current: $17.05
Upside: +193.26%
Jul 8, 2024
Initiates: Outperform
Price Target: $20
Current: $1.03
Upside: +1,841.75%
Jun 7, 2024
Maintains: Buy
Price Target: $36 → $82
Current: $77.99
Upside: +5.14%
May 16, 2024
Maintains: Buy
Price Target: $14 → $16
Current: $4.63
Upside: +245.57%
May 14, 2024
Maintains: Neutral
Price Target: $4 → $3
Current: $3.66
Upside: -18.03%
May 7, 2024
Maintains: Buy
Price Target: $39 → $30
Current: $5.83
Upside: +414.58%
Apr 29, 2024
Maintains: Buy
Price Target: $40 → $22
Current: $4.61
Upside: +377.22%
Apr 2, 2024
Maintains: Buy
Price Target: $20 → $8
Current: $1.64
Upside: +387.80%
Mar 27, 2024
Maintains: Neutral
Price Target: $3.5
Current: $3.38
Upside: +3.55%
Nov 27, 2023
Maintains: Buy
Price Target: $17 → $10
Current: $2.92
Upside: +242.47%
Nov 17, 2023
Maintains: Buy
Price Target: $10 → $9
Current: $1.29
Upside: +597.67%
Aug 23, 2023
Reiterates: Neutral
Price Target: $64
Current: $2.12
Upside: +2,918.87%
Jun 5, 2023
Downgrades: Neutral
Price Target: $17 → $1
Current: $1.98
Upside: -49.49%
Mar 31, 2023
Initiates: Buy
Price Target: $15
Current: $1.91
Upside: +685.34%
Nov 10, 2022
Maintains: Buy
Price Target: $31 → $35
Current: $54.80
Upside: -36.13%
Nov 10, 2022
Maintains: Neutral
Price Target: $9 → $8
Current: $2.91
Upside: +174.91%
May 24, 2022
Maintains: Buy
Price Target: $71 → $57
Current: $43.19
Upside: +31.97%
Apr 19, 2022
Maintains: Sell
Price Target: $8 → $5
Current: $39.86
Upside: -87.46%
Jun 1, 2021
Initiates: Buy
Price Target: $34
Current: $7.26
Upside: +368.32%
Apr 20, 2021
Initiates: Neutral
Price Target: $28
Current: $4.21
Upside: +565.08%
Apr 19, 2021
Initiates: Neutral
Price Target: $31
Current: $23.27
Upside: +33.22%
Mar 2, 2021
Initiates: Sell
Price Target: $19
Current: $0.75
Upside: +2,423.58%
Nov 24, 2020
Initiates: Neutral
Price Target: $4.75
Current: $1.98
Upside: +139.90%
Nov 9, 2020
Upgrades: Buy
Price Target: $36
Current: $15.73
Upside: +128.86%
Oct 21, 2020
Downgrades: Sell
Price Target: n/a
Current: $25.46
Upside: -
Oct 20, 2020
Initiates: Neutral
Price Target: $37
Current: $0.80
Upside: +4,526.74%
Sep 14, 2020
Downgrades: Sell
Price Target: $128
Current: $122.92
Upside: +4.13%